首页> 外文期刊>Diagnostic cytopathology >The Use of Urinary Nuclear Matrix Protein 22 (NMP22) as a Diagnostic Adjunct to Urine Cytology for Monitoring of Recurrent Bladder Cancer-Institutional Experience and Review
【24h】

The Use of Urinary Nuclear Matrix Protein 22 (NMP22) as a Diagnostic Adjunct to Urine Cytology for Monitoring of Recurrent Bladder Cancer-Institutional Experience and Review

机译:尿核基质蛋白22(NMP22)作为尿液细胞学的诊断性辅助手段,用于监测复发性膀胱癌的机构经验和回顾

获取原文
获取原文并翻译 | 示例
           

摘要

BackgroundThis prospective study compares urine NMP22 immunoassay and cytomorphology for detecting recurrent urothelial carcinoma (UC) of the bladder and correlates between NMP22 levels and grade, multiplicity, and size of the tumor. We aimed refining the use of NMP22 test in the management of UC at our institution.
机译:背景这项前瞻性研究比较了尿液NMP22免疫测定和细胞形态学检测膀胱复发性尿路上皮癌(UC)的情况,并将NMP22水平与肿瘤的分级,多样性和大小相关联。我们的目标是完善NMP22测试在我们机构的UC管理中的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号